This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Sanofi-Aventis U.S. LLC
Sanofi-Aventis U.S. LLC, a prominent subsidiary of the global healthcare leader Sanofi, is headquartered in the United States, with significant operations across North America. Founded in 2004, the company has established itself within the pharmaceutical industry, focusing on innovative solutions in areas such as diabetes, cardiovascular health, and rare diseases. Sanofi-Aventis is renowned for its diverse portfolio of core products, including insulin therapies and vaccines, which are distinguished by their commitment to patient-centric care and advanced research. The company has achieved notable milestones, including advancements in biologics and a strong market position as a trusted provider of essential medications. With a dedication to improving health outcomes, Sanofi-Aventis continues to play a vital role in the evolving landscape of global healthcare.
DitchCarbon Score
How does Sanofi-Aventis U.S. LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sanofi-Aventis U.S. LLC's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sanofi-Aventis U.S. LLC, headquartered in the US, currently does not have specific carbon emissions data available for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of Sanofi, which cascades its climate commitments and emissions data from the parent organisation. Sanofi has set various climate initiatives, including targets under the Science Based Targets initiative (SBTi), and participates in the Carbon Disclosure Project (CDP) and RE100, which focuses on renewable energy commitments. However, specific reduction targets or achievements for Sanofi-Aventis U.S. LLC are not detailed in the available information. As a part of the broader Sanofi corporate family, the climate commitments and performance metrics are inherited from the parent company, Sanofi. This relationship underscores the importance of collective action within the pharmaceutical industry to address climate change and reduce carbon footprints.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2011 | 2012 | 2013 | 2015 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 545,114,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 677,549,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 0,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sanofi-Aventis U.S. LLC is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
